Surrozen, Inc.

As of November 6, 2024, Surrozen, Inc. is classified as risky due to its low P/E ratio of 6 and EV to EBITDA ratio of 1.12, despite a high ROE of 214.31% and a strong one-year return of 49.56%, indicating potential overvaluation concerns relative to its peers.

As of November 6, 2024, Surrozen, Inc. is classified as "risky" but appears undervalued with a P/E ratio of 6, a PEG ratio of 0.05, and strong operational metrics, despite a year-to-date stock performance of -37.14% compared to the S&P 500's 2.44%.

As of June 5, 2025, the market trend is mildly bearish, influenced by bearish daily moving averages and KST momentum, despite some conflicting indicators like a mildly bullish MACD and neutral RSI suggesting potential stabilization.

Surrozen, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, with recent net sales of $1 million and a net loss of $27 million. It has a market cap of $78.95 million and key metrics include a P/E ratio of 6.00 and a return on equity of 214.31%.

As of Jun 18, Surrozen, Inc. has a market capitalization of 78.95 million, with net sales of 11.64 million and a net profit of -81.70 million over the latest four quarters. Shareholder's funds are reported at -21.38 million, and total assets amount to 48.47 million.